AAF-cmk sensitizes tumor cells to trail-mediated apoptosis

Leukemia Research

Volumn 28, Issue 1, 2004, Pages 53-61

  Młnarczuk, Izabela ^a,b   Mróz, Paweł ^a   Hoser, Grazyna ^c   Nowis, Dominika ^a   Biały, Łukasz P ^a   Ziemba, Halina ^a   Grzela, Tomasz ^a   Feleszko, Wojciech ^a   Malejczyk, Jacek ^a   Wójcik, Cezary ^a   Jakóbisiak, Marek ^a   Goła̧b, Jakub ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b HUMBOLDT UNIVERSITY   (Germany)

^c Medical Center of Postgraduate Education   (Poland)

Author keywords

AAF cmk; Apoptosis; Lymphoma; TNF; TRAIL; Tripeptidylpeptidase II

Indexed keywords

ALANYLALANYLPHENYLALANYL CHLOROMETHYL KETONE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; PEPTIDE DERIVATIVE; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG POTENTIATION; ELECTRON MICROSCOPY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

EID: 10744230904     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00122-X     Document Type: Article

References (41)

1. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425.
2. Wójcik C., Stokłosa T., Giermasz A., Golła̧b J., Zagozdzon R., Kawiak J., et al. Apoptosis induced in L1210 leukemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. Apoptosis. 2:1997;455.
3. Wójcik C. Proteasomes in apoptosis: villains or guardians? Cell. Mol. Life Sci. 56:1999;908.
4. Wójcik C., Schroeter D., Stoehr M., Wilk S., Paweletz N. An inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces arrest in G2-phase and metaphase in HeLa cells. Eur. J. Cell. Biol. 70:1996;172.
5. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol. 28:2001;613.
6. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 7:2002;9.
7. Bonn D. Targeting protein breakdown to treat cancer. Mol. Med. Today. 5:1999;48.
8. Gavioli R., Frisan T., Vertuani S., Bornkamm G.W., Masucci M.G. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat. Cell. Biol. 3:2001;283.
9. Pleban E., Bury M., Mlłynarczuk I., Wójcik C. Effects of proteasome inhibitor PSI on neoplastic and non-transformed cell lines. Folia Histochem. Cyto. 39:2001;133.
10. Wang E.W., Kessler B.M., Borodovsky A., Cravatt B.F., Bogyo M., Ploegh H.L., Glas R. Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity. Proc. Natl. Acad. Sci. U.S.A. 97:2000;9990.
11. Geier E., Pfeifer G., Wilm M., Lucchiari-Hartz M., Baumeister W., Eichmann K., Niedermann G. A giant protease with potential to substitute for some functions of the proteasome. Science. 283:1999;978.
12. Glas R., Bogyo M., McMaster J.S., Gaczynska M., Ploegh H.L. A proteolytic system that compensates for loss of proteasome function. Nature. 392:1998;618.
13. Yao T., Cohen R.E. Giant proteases: beyond the proteasome. Curr. Biol. 9:1999;551.
14. Balow R.M., Tomkinson B., Ragnarsson U., Zetterqvist O. Purification, substrate specificity, and classification of tripeptidyl peptidase II. J. Biol. Chem. 261:1986;2409.
15. Rose C., Vargas F., Facchinetti P., Bourgeat P., Bambal R.B., Bishop P.B., et al. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature. 380:1996;403.
16. Chowdhary B.P., Johansson M., Gu F., Brauner-Nielsen P., Tomkinson B., Andersson L., et al. Assignment of the linkage group EAM-TYRP2-TPP2 to chromosome 11 in pigs by in situ hybridization mapping of the TPP2 gene. Chromosome Res. 1:1993;175.
17. Renn S.C., Tomkinson B., Taghert P.H. Characterization and cloning of tripeptidyl peptidase II from the fruit fly, Drosophila melanogaster. J. Biol. Chem. 273:1998;19173.
18. Tomkinson B., Jonsson A.K. Characterization of cDNA for human tripeptidyl peptidase II: the N-terminal part of the enzyme is similar to subtilisin. Biochemistry. 30:1991;168.
19. Hasselgren P.O., Wray C., Mammen J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem. Biophys. Res. Commun. 290:2002;1.
20. Bury M., Młnarczuk I., Pleban E., Hoser G., Kawiak J., Wójcik C. Effects of an inhibitor of tripeptidyl peptidase II (Ala-Ala-Phe-chloromethylketone) and its combination with an inhibitor of the chymotrypsin-like activity of the proteasome (PSI) on apoptosis, cell cycle and proteasome activity in U937 cells. Folia Histochem. Cyto. 39:2001;131.
21. Treon S., Mitsiades C., Poulaki V., Anderson K., Mitsiades N. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias. Expert Opin. Investig. Drugs. 10:2001;1521.
22. Kayagaki N., Yamaguchi N., Nakayama M., Takeda K., Akiba H., Tsutsui H., et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 163:1999;1906.
23. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med. 5:1999;157.
24. Park J.W., Choi Y.J., Jang M.A., Baek S.H., Lim J.H., Passaniti T., et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem. Biophys. Res. Commun. 286:2001;726.
25. Medema J.P., Scaffidi C., Kischkel F.C., Shevchenko A., Mann M., Krammer P.H., et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16:1997;2794.
26. Griffith T.S., Wiley S.R., Kubin M.Z., Sedger L.M., Maliszewski C.R., Fanger N.A. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189:1999;1343.
27. Jo M., Kim T., Seol D., Esplen J.E., Dorko K., Billar T.R., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis inducing ligand. Nature Med. 6:2000;564.
28. Młynarczuk I., Hoser G., Grzela T., Stokłosa T., Wójcik C., Malejczyk J., et al. Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in human promonocytic leukemic U937 cells. Anticancer Res. 21:2001;1237.
29. Gołccb J., Stokłosa T., Czajka A., Da̧browska A., Jakóbisiak M., Zagozdzon R., et al. Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res. 20:2000;1717.
30. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:1997;5386.
31. Garcia-Calvo M., Peterson E., Leiting B., Ruel R., Nicholson D., Thornberry N. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 273:1998;32608.
32. goła̧b J., Nowis D., Skrzycki M., Czeczot H., Anna Baranczyk-Kuzma A. Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol: a superoxide dismutase inhibitor. J. Biol. Chem. 278:2003;407.
33. Homburg C., Haas M., Borne A., Verhoeven A., Reutelingsperger C., Roos D. Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro. Blood. 85:1995;532.
34. Boersma A., Nooter K., Burger H., Kortland C., Stoter G. Expression of the apoptosis-associated proteins Bcl-2 and Bax was quantitated by flow cytometry (FCM) in chemosensitive testicular germ-cell tumor NT2 cells, and the results were compared with those obtained by Western blotting. NT2 cells were incubated with cisplatin. Cytometry. 27:1997;275.
35. Wyllie A., Kerr J., Currie A. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68:1980;251.
36. Ihara T., Yamamoto T., Sugamata M., Okumura H., Ueno Y. The process of ultrastructural changes from nuclei to apoptotic body. Virchows Arch. 433:1998;443.
37. Maeno E., Ishizaki Y., Kanaseki T., Hazama A., Okada Y. Normotonic cell shrinkage because of disordered volume regulation is an early prerequisite to apoptosis. Proc. Natl. Acad. Sci. U.S.A. 97:2000;9487.
38. Soligo D., Servida F., Delia D., Fontanella E., Lamorte G., Caneva L., et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and maxlignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br. J. Haematol. 113:2001;126.
39. Fulda S., Friesen C., Debatin K.M. Molecular determinants of apoptosis induced by cytotoxic drugs. Klinische Padiatrie. 210:1998;148.
40. Princiotta M.F., Schubert U., Chen W., Bennink J.R., Myung J., Crews C.M., et al. Cells adapted to the proteasome inhibitor 4-hydroxy-5-iodo-3- nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival. Proc. Natl. Acad. Sci. U.S.A. 98:2001;513.
41. Page A.E., Fuller K., Chambers T.J., Warburton M.J. Purification and characterization of a tripeptidyl peptidase I from human osteoclastomas: evidence for its role in bone resorption. Arch. Biochem. Biophys. 306:1993;354.